RESERPINE; TRICHLORMETHIAZIDE - Generic Drug Details
What are the generic drug sources for reserpine; trichlormethiazide and what is the scope of freedom to operate?
Reserpine; trichlormethiazide
is the generic ingredient in four branded drugs marketed by Sanofi Aventis Us, Schering, and Watson Labs, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.Summary for RESERPINE; TRICHLORMETHIAZIDE
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 3 |
| NDAs: | 3 |
| DailyMed Link: | RESERPINE; TRICHLORMETHIAZIDE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for RESERPINE; TRICHLORMETHIAZIDE
US Patents and Regulatory Information for RESERPINE; TRICHLORMETHIAZIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | METATENSIN #2 | reserpine; trichlormethiazide | TABLET;ORAL | 012972-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Watson Labs | TRICHLORMETHIAZIDE W/ RESERPINE | reserpine; trichlormethiazide | TABLET;ORAL | 085248-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Schering | NAQUIVAL | reserpine; trichlormethiazide | TABLET;ORAL | 012265-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sanofi Aventis Us | METATENSIN #4 | reserpine; trichlormethiazide | TABLET;ORAL | 012972-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
